A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.

Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line (IL) therapy.

For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.